Positive News SentimentPositive NewsNASDAQ:ELEV Elevation Oncology (ELEV) Stock Price, News & Analysis $0.57 -0.03 (-4.96%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Elevation Oncology Stock (NASDAQ:ELEV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Elevation Oncology alerts:Sign Up Key Stats Today's Range$0.57▼$0.6250-Day Range$0.50▼$0.8152-Week Range$0.36▼$5.83Volume408,808 shsAverage Volume1.59 million shsMarket Capitalization$33.95 millionP/E RatioN/ADividend YieldN/APrice Target$7.80Consensus RatingBuy Company OverviewElevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Elevation Oncology Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks54th Percentile Overall ScoreELEV MarketRank™: Elevation Oncology scored higher than 54% of companies evaluated by MarketBeat, and ranked 571st out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingElevation Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageElevation Oncology has only been the subject of 2 research reports in the past 90 days.Read more about Elevation Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Elevation Oncology are expected to decrease in the coming year, from ($0.82) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Elevation Oncology is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elevation Oncology is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElevation Oncology has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Elevation Oncology's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.90% of the float of Elevation Oncology has been sold short.Short Interest Ratio / Days to CoverElevation Oncology has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Elevation Oncology has recently decreased by 3.25%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElevation Oncology does not currently pay a dividend.Dividend GrowthElevation Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.90% of the float of Elevation Oncology has been sold short.Short Interest Ratio / Days to CoverElevation Oncology has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Elevation Oncology has recently decreased by 3.25%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News SentimentN/A News SentimentElevation Oncology has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.Search Interest11 people have searched for ELEV on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Elevation Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Elevation Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.10% of the stock of Elevation Oncology is held by insiders.Percentage Held by Institutions83.70% of the stock of Elevation Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Elevation Oncology's insider trading history. Receive ELEV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address ELEV Stock News HeadlinesComparing Cellectis (NASDAQ:CLLS) & Elevation Oncology (NASDAQ:ELEV)October 22, 2024 | americanbankingnews.comEmpery Asset Management's Strategic Acquisition in Elevation OncologyOctober 9, 2024 | gurufocus.comProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.October 31, 2024 | Weiss Ratings (Ad)Elevation Oncology Gets FDA Fast-Track Designation for EO-3021September 24, 2024 | marketwatch.comElevation Oncology Receives Fast Track Designation For EO-3021 - Quick FactsSeptember 24, 2024 | markets.businessinsider.comElevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2September 23, 2024 | prnewswire.comElevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | prnewswire.comElevation Oncology, Inc. (ELEV)August 16, 2024 | finance.yahoo.comSee More Headlines ELEV Stock Analysis - Frequently Asked Questions How have ELEV shares performed this year? Elevation Oncology's stock was trading at $0.5370 at the beginning of 2024. Since then, ELEV shares have increased by 6.9% and is now trading at $0.5743. View the best growth stocks for 2024 here. How were Elevation Oncology's earnings last quarter? Elevation Oncology, Inc. (NASDAQ:ELEV) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. When did Elevation Oncology IPO? Elevation Oncology (ELEV) raised $1 billion in an initial public offering on Friday, June 25th 2021. The company issued 63,000,000 shares at $15.00-$17.00 per share. Who are Elevation Oncology's major shareholders? Elevation Oncology's top institutional investors include SG Americas Securities LLC (0.08%). View institutional ownership trends. How do I buy shares of Elevation Oncology? Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Elevation Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elevation Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings8/06/2024Today10/31/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELEV CUSIPN/A CIK1783032 Webwww.elevationoncology.com Phone716-371-1125FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$7.80 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+1,200.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.97% Return on Assets-38.49% Debt Debt-to-Equity Ratio0.38 Current Ratio41.10 Quick Ratio41.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book0.47Miscellaneous Outstanding Shares59,107,000Free Float54,319,000Market Cap$35.46 million OptionableOptionable Beta1.22 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:ELEV) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevation Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.